Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

Sponsored by Shanghai University of Traditional Chinese Medicine

About this trial

Last updated 13 years ago

Study ID

06DZ19728

Status

Completed

Type

Interventional

Phase

Phase 4

Placebo

Accepting

18 to 65 Years

All Sexes

Trial Timing

Ended 17 years ago

What is this trial about?

The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM). The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.

What are the participation requirements?

Inclusion Criteria

* Clinical diagnosis of B Post hepatitic cirrhosis.

* Male or female patients between 18~65 years old.

* Written informed consent.

Exclusion Criteria

* Child-Pugh C above 12, or ALT > 2×ULN, TBiL > 2×ULN, or combined with hepatic encephacopathy, Obstinate ascites, bleeding tendency, hepato-renal syndrome, or primary liver cancer.

* Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease.

* Deformed man by the law.

* Pregnancy or breast feeding women, or unwilling to have contraception.

* Irritability body constitution, or irritability of the Fuzheng Huayu Capsules.

* Enter other trials lately one month.

* Other cause of cirrhosis.